(R)-70, or R-70, is a non-hallucinogenic selective serotonin 5-HT<sub>2</sub> receptor moderate-efficacy partial agonist of the tetrahydropyridinylpyrrolopyridine family related to the psychedelic tryptamines. It shows preference for activation of the serotonin 5-HT<sub>2A</sub> receptor of about 6.4-fold relative to the serotonin 5-HT<sub>2B</sub> receptor and of about 30-fold relative to the serotonin 5-HT<sub>2C</sub> receptor. The drug is a biased agonist of the serotonin 5-HT<sub>2A</sub> receptor, activating G<sub>q</sub> protein signaling more readily than ò-arrestin2 signaling. It did not significantly produce the head-twitch response in mice, but did produce antidepressant-like effects. (R)-70, along with its close analogue (R)-69, was first described in the scientific literature by Bryan L. Roth and colleagues in 2022. It was identified via an ultra-large-scale docking campaign for the serotonin 5-HT<sub>2A</sub> receptor.